ArticleJournal of medical biochemistry2025
Association of antioxidant markers (SOD, GSH, NO, Catalase) with ischemic stroke severity and recovery outcomes.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MiR-124 alleviates cerebral ischemia-reperfusion injury by targeting SLC1A5 to inhibit neuronal ferroptosis.Iranian journal of basic medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This randomised controlled trial aimed to investigate the relationship between antioxidant markers (Superoxide Dismutase [SOD], Glutathione [GSH], Catalase, and Nitric Oxide [NO]) and the severity of ischemic stroke in affected individuals. Methods: A single-blind randomised controlled trial was conducted from June 2022 to November 2024, including 364 patients aged 45-80 years diagnosed with ischemic stroke. Participants were randomly divided into two groups: Group A (n=193) received standard stroke rehabilitation therapy, while Group B (n=171) received additional antioxidant support. Serum levels of SOD, GSH, Catalase, and NO were measured. Stroke severity was evaluated using the modified Rankin Scale (mRS) and NIH Stroke Scale (NIHSS), with follow-up assessments at 2, 4, and 6 months post-treatment. Results: Among the 364 participants, 203 (55.7%) were male, and 161 (44.3%) were female, with a mean age of 67.3±12.2 years. Serum SOD levels were higher in the experimental group (16.3±3.7 U/mL) compared to the control group (12.5±4.1 U/mL, p=0.014). GSH levels were also significantly higher in the experimental group (178±31 mmol/L) than in the control group (145±26 mmol/L, p=0.032). NO levels were higher in the experimental group (42.1±8.6 mmol/L) than in the control group (35.4±7.3 mmol/L, p=0.021). Catalase levels were 52.3±11.1 U/mL in the experimental group and 49.6±10.2 U/mL in the control group, with no significant difference between the groups (p=0.213). Significant inverse correlations were found between SOD, GSH, and NO levels and stroke severity (p<0.05), but catalase showed no such correlation (p=0.513). Conclusions: This study identified a significant relationship between higher levels of SOD, GSH, and NO and improved stroke recovery, whereas catalase did not exhibit a meaningful association with stroke severity or functional outcomes. These findings highlight the potential role of specific antioxidant markers in stroke prognosis and recovery while suggesting that catalase may not play a critical role in ischemic stroke outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.